Annual report pursuant to Section 13 and 15(d)

PF MEDICAL (Details Narrative)

v3.22.1
PF MEDICAL (Details Narrative) - USD ($)
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 30, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
non-controlling interest $ (1,742,000)  
Loss on deconsolidation of subsidiary (Note 14) 1,062,000  
Legal and accounting costs $ 94,000    
Sales Agreement [Member]      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Equity Method Investment, Ownership Percentage 60.54%   60.54%
Notes receivable, amount     $ 47,000
Trade payables     $ 2,537,000
Acquired price $ 10    
non-controlling interest 1,004,000    
Loss on deconsolidation of subsidiary (Note 14) $ 902,000